Compare ILMN & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ILMN | KVUE |
|---|---|---|
| Founded | 1998 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0B | 34.2B |
| IPO Year | 2000 | 2023 |
| Metric | ILMN | KVUE |
|---|---|---|
| Price | $276.29 | $17.68 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 14 |
| Target Price | ★ $232.15 | $19.50 |
| AVG Volume (30 Days) | 2.8M | ★ 22.3M |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 4.74% |
| EPS Growth | ★ 170.87 | 40.74 |
| EPS | ★ 2.22 | 0.48 |
| Revenue | $4,343,000,000.00 | ★ $15,124,000,000.00 |
| Revenue This Year | $6.48 | $3.12 |
| Revenue Next Year | $6.46 | $2.38 |
| P/E Ratio | $119.18 | ★ $36.94 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $88.00 | $14.02 |
| 52 Week High | $309.35 | $20.13 |
| Indicator | ILMN | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 62.08 | 45.12 |
| Support Level | $118.76 | $17.47 |
| Resistance Level | N/A | $17.90 |
| Average True Range (ATR) | 15.16 | 0.24 |
| MACD | -0.76 | 0.05 |
| Stochastic Oscillator | 55.42 | 58.47 |
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.